DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- Jun 17, 2026
- Amount
- Program total $8.5M
- Closes
- Sep 18, 2026 (in 2 days)
Similar opportunities open now
- DoW Duchenne Muscular Dystrophy, Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 2 days
- DoW Spinal Cord Injury, Clinical Translation Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 57 days
- DOW Combat Readiness – Medical Research Program Translational Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 63 days
- DoW Alzheimer’s Transforming Care AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 8 days
- DoW Alzheimer’s Transforming Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 8 days
Classification and identifiers
- Solicitation number
- HT942526DMDRPCTRA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $8.5M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged. Distinctive Features: The FY26 CTRA offers two funding levels: • Funding Level 1 to support smaller, less complex preclinical and/or clinical research. • Funding Level 2 to support larger, more complex preclinical and/or clinical research. The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partner...